Dianthus Therapeutics Inc (DNTH)

Mar 11, 2025, 4:01 PM EDT - 23 days ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

Mar 5, 2025, 7:00 AM EST - 4 weeks ago

Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors

Feb 26, 2025, 7:00 AM EST - 5 weeks ago

Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences

Jan 30, 2025, 7:00 AM EST - 2 months ago

Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

Jan 8, 2025, 7:00 AM EST - 3 months ago

Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 7, 2024, 4:01 PM EST - 5 months ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Nov 4, 2024, 7:00 AM EST - 5 months ago

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

Oct 15, 2024, 7:00 AM EDT - 6 months ago

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting

Aug 8, 2024, 4:01 PM EDT - 8 months ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

Jul 29, 2024, 3:45 PM EDT - 8 months ago

Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition

Jun 28, 2024, 11:30 AM EDT - 10 months ago

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

Jun 12, 2024, 7:00 AM EDT - 10 months ago

Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

May 30, 2024, 4:30 PM EDT - 11 months ago

Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 9, 2024, 4:01 PM EDT - 11 months ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

May 8, 2024, 4:30 PM EDT - 11 months ago

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

May 3, 2024, 4:30 PM EDT - 11 months ago

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 11, 2024, 7:30 AM EDT - 1 year ago

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Mar 7, 2024, 4:30 PM EST - 1 year ago

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 26, 2024, 7:00 AM EST - 1 year ago

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

Sep 11, 2023, 11:33 AM EDT - 1 year ago

Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split

Aug 7, 2023, 4:03 PM EDT - 1 year ago

MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA

May 3, 2023, 7:00 AM EDT - 2 years ago

Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

Mar 31, 2023, 4:10 PM EDT - 2 years ago

Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

Feb 2, 2023, 4:05 PM EST - 2 years ago

Magenta Therapeutics to Explore Strategic Alternatives

Jan 25, 2023, 4:05 PM EST - 2 years ago

Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety

Dec 20, 2022, 9:00 AM EST - 2 years ago

Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial

Dec 12, 2022, 4:30 PM EST - 2 years ago

Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates

Dec 12, 2022, 8:00 AM EST - 2 years ago

Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial

Nov 3, 2022, 9:01 AM EDT - 2 years ago

Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights

Nov 3, 2022, 9:01 AM EDT - 2 years ago

Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting

Nov 1, 2022, 8:00 AM EDT - 2 years ago

Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference

Aug 17, 2022, 8:00 AM EDT - 2 years ago

Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

Aug 4, 2022, 8:00 AM EDT - 2 years ago

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

Aug 2, 2022, 8:00 AM EDT - 2 years ago

Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference

May 16, 2022, 8:00 AM EDT - 3 years ago

Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights

Apr 14, 2022, 12:23 PM EDT - 3 years ago

Magenta Therapeutics Trims R&D, Cuts Workforce

Apr 14, 2022, 8:00 AM EDT - 3 years ago

Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway

Mar 8, 2022, 8:00 AM EST - 3 years ago

Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights

Mar 3, 2022, 8:00 AM EST - 3 years ago

Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference

Jan 10, 2022, 8:00 AM EST - 3 years ago

Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022

Jan 5, 2022, 8:00 AM EST - 3 years ago

Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B.

Dec 14, 2021, 9:00 AM EST - 3 years ago

Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting

Nov 4, 2021, 9:10 AM EDT - 3 years ago

Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights

Nov 4, 2021, 9:09 AM EDT - 3 years ago

Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting

Oct 4, 2021, 8:00 AM EDT - 3 years ago

Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer

Sep 21, 2021, 8:00 AM EDT - 3 years ago

Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference

Sep 19, 2021, 6:06 AM EDT - 3 years ago

Week 38 MDA Breakout Stocks - September 2021: Short-Term Picks To Give You An Edge

AAPL CAT CRM DOW GS INTC JNJ